![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Arkis Wins FDA Clearance for CerebroFlo Catheter
Arkis Wins FDA Clearance for CerebroFlo Catheter
![Grey Approved Stamp](https://www.fdanews.com/ext/resources/test/Drug-Images4/Grey_Approved_Stamp.gif?t=1576541258&width=430)
September 25, 2017
Arkis Biosciences’ new catheter intended for external ventricular drainage of cerebrospinal fluid has received FDA marketing clearance.
CerebroFlo is the first neuro catheter to incorporate Endexo, a catheter technology for reducing protein adhesions and activation with demonstrated success in in vitro studies.
Arkis was awarded an exclusive license of the Endexo technology from Interface Biologics for neurological cerebrospinal fluid applications.
Upcoming Events
-
21Oct